EXERCISE PROGRAM FOR THE PREVENTION OF OSTEOPOROTIC FRACTURE
With
Belinda Beck,
Professor of Exercise Science,
Griffith University &
Owner and Director, The Bone Clinic &
Member of Medical and Scientific Advisory Committee
Healthy Bones Australia (formerly Osteoporosis Australia)
RESEARCHER PROFILE
Filmed in Southport, Queensland, Australia | May 2025
Dr Beck is an international leader in the effects of mechanical loading on bone health. Dr Beck graduated from The University of Queensland (BHMS[Ed]) and the University of Oregon (MSc and PhD) and completed a postdoctoral research fellowship in the Stanford University School of Medicine (California, USA.) She is a Professor of Exercise Science at Griffith University Gold Coast campus, where she has led the Bone Densitometry Research Laboratory since 2004.
Dr Beck has been awarded $7.6M in research grant funding to work on both animal and human models, from basic to clinical research. She has extensive experience leading clinical trials and the development of methodologies in musculoskeletal measurement. Her particular focuses have been exercise interventions across the lifespan for bone health, and bone stress injuries in athlete and military populations. In recent years she developed the first effective exercise program for the prevention of osteoporotic fracture.
The impact and significance of her work are reflected in 108 peer-reviewed journal articles (80% Q1 journals, 83.3% in top 25% journals by CiteScore), 7 chapters and 16 consumer publications in her field. Over 35% of her publications are in the top 10% most viewed publications worldwide (SciVal).
She has supervised 11 PhD, 5 Masters and 13 Honours students to completion and is currently supervising 2 PhD students, 1 Masters and 1 Honours student, along with three research associates (fellows and assistants). She has delivered 40 invited presentations worldwide (e.g., London, Italy, France, Germany, and the USA) and 57 nationally. She is a Board member of the International Osteoporosis Foundation Capture the Fracture programme, Sports Medicine Australia, the Australian and New Zealand Bone and Mineral Society and a Fellow of the American Society of Bone and Mineral Research, the American College of Sports Medicine, Sports Medicine Australia and Exercise Sports Science Australia.
Dr Beck’s research impact stems from the results of successful and innovative clinical trials and methodological studies that have changed practice in the fields of osteoporosis and military medicine and research practice. The implementation of her research outcomes in the real world seek to make genuine and significant differences to the quality and productivity of people.
Source: Adapted from supplied copy
-
Biostatistics in Clinical Trials
As a biostatistician working in research and clinical settings, Kate Francis plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
-
Electrical stimulation on organic conductors
Professor Gordon Wallace AO is the Founder and Director of the Intelligent Polymer Research Institute (IPRI) at the University of Wollongong and Founding Director of the Australian National Fabrication Facility (ANFF) Materials Node. He was previously the Executive Director of the ARC Centre of Excellence for Electromaterials Science (ACES).
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
